Plus Therapeutics Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Stockholders' Equity Requirement

Reuters

06-07

Plus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Stockholders' Equity Requirement

Plus Therapeutics Inc. announced on June 3, 2025, that it has received a notice from the Nasdaq Listing Qualifications Department regarding non-compliance with the Nasdaq Listing Rule 5550(b)(1), which mandates a minimum of $2.5 million in stockholders' equity for continued listing on the Nasdaq Capital Market. The company's recent quarterly report revealed a deficit of $23,641,000, prompting Nasdaq to consider delisting its securities. Plus Therapeutics plans to appeal the decision and request a hearing before a Nasdaq Hearings Panel to address the issue and seek compliance. The company aims to resolve the matter while continuing to trade on Nasdaq during the appeal process.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-137089), on June 06, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2541987298"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541987298\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2541987298?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-07 04:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541987298","market":"us","top_or_hot":-1,"title":"Plus Therapeutics Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Stockholders' Equity Requirement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Plus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Stockholders' Equity Requirement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Plus Therapeutics Inc. announced on June 3, 2025, that it has received a notice from the Nasdaq Listing Qualifications Department regarding non-compliance with the Nasdaq Listing Rule 5550(b)(1), which mandates a minimum of $2.5 million in stockholders' equity for continued listing on the Nasdaq Capital Market. The company's recent quarterly report revealed a deficit of $23,641,000, prompting Nasdaq to consider delisting its securities. Plus Therapeutics plans to appeal the decision and request a hearing before a Nasdaq Hearings Panel to address the issue and seek compliance. The company aims to resolve the matter while continuing to trade on Nasdaq during the appeal process.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-137089), on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Plus Therapeutics Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Stockholders' Equity Requirement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPlus Therapeutics Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Stockholders' Equity Requirement\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-07 04:22</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Plus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Stockholders' Equity Requirement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Plus Therapeutics Inc. announced on June 3, 2025, that it has received a notice from the Nasdaq Listing Qualifications Department regarding non-compliance with the Nasdaq Listing Rule 5550(b)(1), which mandates a minimum of $2.5 million in stockholders' equity for continued listing on the Nasdaq Capital Market. The company's recent quarterly report revealed a deficit of $23,641,000, prompting Nasdaq to consider delisting its securities. Plus Therapeutics plans to appeal the decision and request a hearing before a Nasdaq Hearings Panel to address the issue and seek compliance. The company aims to resolve the matter while continuing to trade on Nasdaq during the appeal process.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-137089), on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL7fC6Qq:1","article_id":"2541987298","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541987298","pubTimestamp":1749241373,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Plus Therapeutics Inc. announced on June 3, 2025, that it has received a notice from the Nasdaq Listing Qualifications Department regarding non-compliance with the Nasdaq Listing Rule 5550, which mandates a minimum of $2.5 million in stockholders' equity for continued listing on the Nasdaq Capital Market. The company's recent quarterly report revealed a deficit of $23,641,000, prompting Nasdaq to consider delisting its securities. Plus Therapeutics plans to appeal the decision and request a hearing before a Nasdaq Hearings Panel to address the issue and seek compliance. The company aims to resolve the matter while continuing to trade on Nasdaq during the appeal process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics I","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PSTV":"Plus Therapeutics, Inc."},"translate_title":"Plus Therapeutics Inc.因不遵守股东权益要求而面临纳斯达克退市风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSTV":0.9},"content_text":"Plus Therapeutics Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Stockholders' Equity Requirement\n    \n\n        Plus Therapeutics Inc. announced on June 3, 2025, that it has received a notice from the Nasdaq Listing Qualifications Department regarding non-compliance with the Nasdaq Listing Rule 5550(b)(1), which mandates a minimum of $2.5 million in stockholders' equity for continued listing on the Nasdaq Capital Market. The company's recent quarterly report revealed a deficit of $23,641,000, prompting Nasdaq to consider delisting its securities. Plus Therapeutics plans to appeal the decision and request a hearing before a Nasdaq Hearings Panel to address the issue and seek compliance. The company aims to resolve the matter while continuing to trade on Nasdaq during the appeal process.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-137089), on June 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}